• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接种阿斯利康 COVID-19 疫苗后依库溴铵综合征和急性躁狂症的序贯激发。

Sequential provocation of Ekbom's syndrome and acute mania following AstraZeneca COVID-19 vaccination.

机构信息

Department of Psychiatry, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.

Department of Psychiatry, China Medical University Hsinchu Hospital, China Medical University, Hsinchu, Taiwan.

出版信息

Asian J Psychiatr. 2023 May;83:103569. doi: 10.1016/j.ajp.2023.103569. Epub 2023 Mar 25.

DOI:10.1016/j.ajp.2023.103569
PMID:37012199
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10039778/
Abstract

ChAdOx1 nCoV-19 vaccine (so called AZ vaccine), is widely used to prevent the SARS-CoV-2 pandemic and shows powerful effectiveness to deter community transmission. There are common immunogenicity-related side effects such as fever, myalgia, lethargy, and headache; however, rare report on the neuropsychiatric problems (Ramasamy et al., 2021). In Taiwan, more than 15,200,000 doses of AZ vaccine were injected by the end of 2022. Here we presented a unique case with separated episode of Ekbom's syndrome, also called delusion of parasitosis, and mania following successive AZ vaccination in three-month interval.

摘要

ChAdOx1 nCoV-19 疫苗(又称 AZ 疫苗)被广泛用于预防 SARS-CoV-2 大流行,并显示出强大的效力来阻止社区传播。它有常见的与免疫原性相关的副作用,如发热、肌痛、乏力和头痛;然而,关于神经精神问题的罕见报告(Ramasamy 等人,2021 年)。在台湾,到 2022 年底,已经注射了超过 1520 万剂的 AZ 疫苗。在这里,我们报告了一个独特的病例,该病例在连续接种 AZ 疫苗三个月的间隔中出现了 Ekbom 综合征(也称为寄生虫妄想症)和躁狂症的分离发作。

相似文献

1
Sequential provocation of Ekbom's syndrome and acute mania following AstraZeneca COVID-19 vaccination.接种阿斯利康 COVID-19 疫苗后依库溴铵综合征和急性躁狂症的序贯激发。
Asian J Psychiatr. 2023 May;83:103569. doi: 10.1016/j.ajp.2023.103569. Epub 2023 Mar 25.
2
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.一剂接种和加强针接种时间对 ChAdOx1 nCoV-19(阿斯利康)疫苗免疫原性和有效性的影响:四项随机试验的 pooled 分析。
Lancet. 2021 Mar 6;397(10277):881-891. doi: 10.1016/S0140-6736(21)00432-3. Epub 2021 Feb 19.
3
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.《6-17 岁儿童中 ChAdOx1 nCoV-19(AZD1222)疫苗的安全性和免疫原性:COV006 的初步报告,一项 2 期、单盲、随机、对照试验》
Lancet. 2022 Jun 11;399(10342):2212-2225. doi: 10.1016/S0140-6736(22)00770-X.
4
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.鼻内接种腺病毒载体 COVID-19 疫苗的耐受性和免疫原性:一项开放性、部分随机、递增剂量的 I 期临床试验。
EBioMedicine. 2022 Nov;85:104298. doi: 10.1016/j.ebiom.2022.104298. Epub 2022 Oct 10.
5
A Case of Heart Transplantation for Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccination.腺病毒载体新冠疫苗(ChAdOx1 nCoV-19)接种后暴发性心肌炎行心脏移植 1 例
J Korean Med Sci. 2022 Apr 4;37(13):e104. doi: 10.3346/jkms.2022.37.e104.
6
MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.接种 2019 年冠状病毒病(SARS-CoV-2)疫苗后发生 MOG 脑炎:病例报告及文献综述。
J Neurol. 2022 Oct;269(10):5198-5212. doi: 10.1007/s00415-022-11194-9. Epub 2022 Jun 23.
7
Generalized Edema and Pseudothrombocytopenia After ChAdOx1 nCoV-19 COVID-19 Vaccination: A Case Report.接种 ChAdOx1 nCoV-19 新冠疫苗后出现全身性水肿和假性血小板减少症:1 例病例报告。
Front Public Health. 2022 May 27;10:907652. doi: 10.3389/fpubh.2022.907652. eCollection 2022.
8
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.COVID-19 疫苗效力下降和加强针的有效性和副作用:来自 ZOE COVID 研究的一项前瞻性社区研究。
Lancet Infect Dis. 2022 Jul;22(7):1002-1010. doi: 10.1016/S1473-3099(22)00146-3. Epub 2022 Apr 8.
9
Case reports of management of aplastic anemia after COVID-19 vaccination: a single institute experience in Taiwan.台湾单中心经验:COVID-19 疫苗接种后再生障碍性贫血的管理病例报告。
Int J Hematol. 2023 Jan;117(1):149-152. doi: 10.1007/s12185-022-03445-2. Epub 2022 Sep 4.
10
Injuries and deaths following Covid-19 vaccination: The ethical and legal case for compensation.接种新冠疫苗后的伤害和死亡:赔偿的伦理和法律依据。
Indian J Med Ethics. 2024 Jul-Sep;IX(3):175-179. doi: 10.20529/IJME.2024.041.

引用本文的文献

1
New-onset psychosis following COVID-19 vaccination: a systematic review.新冠病毒疫苗接种后新发精神病:一项系统综述
Front Psychiatry. 2024 Apr 12;15:1360338. doi: 10.3389/fpsyt.2024.1360338. eCollection 2024.

本文引用的文献

1
Moving beyond COVID.超越新冠疫情
Asian J Psychiatr. 2022 Jul;73:103178. doi: 10.1016/j.ajp.2022.103178. Epub 2022 May 31.
2
Inflammation and Brain Structure in Schizophrenia and Other Neuropsychiatric Disorders: A Mendelian Randomization Study.精神分裂症和其他神经精神疾病中的炎症与脑结构:一项孟德尔随机研究。
JAMA Psychiatry. 2022 May 1;79(5):498-507. doi: 10.1001/jamapsychiatry.2022.0407.
3
Hyperacute reversible encephalopathy related to cytokine storm following COVID-19 vaccine.与 COVID-19 疫苗后细胞因子风暴相关的超急性可逆性脑病。
J Neuroimmunol. 2021 Sep 15;358:577661. doi: 10.1016/j.jneuroim.2021.577661. Epub 2021 Jul 13.
4
Inflammatory signaling mechanisms in bipolar disorder.双相情感障碍中的炎症信号传导机制。
J Biomed Sci. 2021 Jun 11;28(1):45. doi: 10.1186/s12929-021-00742-6.
5
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.在年轻和老年成年人中进行的一次单盲、随机、对照、2/3 期试验中,观察 ChAdOx1 nCoV-19 疫苗在初免-加强免疫方案中的安全性和免疫原性(COV002)。
Lancet. 2021 Dec 19;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1. Epub 2020 Nov 19.
6
Inflammation in Schizophrenia: Pathogenetic Aspects and Therapeutic Considerations.精神分裂症中的炎症:发病机制方面和治疗考虑。
Schizophr Bull. 2018 Aug 20;44(5):973-982. doi: 10.1093/schbul/sby024.